Imovane
(Zopiclone)PreclinicalSmall molecule
Zopiclone is a sleeping pill used to treat insomnia by helping people fall asleep and stay asleep through the night.[1] Imovane is currently being investigated across 1 indication[3], with its most advanced program in Preclinical.[1]
Imovane is one of 9 small molecule programs targeting Multimodal Analgesia. It is currently in Preclinical.
1
Indications
24
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Multimodal Analgesia
#DrugCompanyPhaseTrials
1Neurontin
VViatris Specialty LLC
Approved
Tylenol
KKenvue Brands
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Acupan
YYonsei University
Preclinical
Valium
Akero TherapeuticsPreclinical
Dexketoprofen Trometamol
MenariniPreclinical
Celebrex
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Imovane
TTaisho Pharmaceutical Co., Ltd.
Preclinical
Naprosyn
LLogical Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Insomnia5 trials
Driving5 trials
Elderly3 trials
Major Depressive Disorder1 trial
9 more indications
Sleep1 trial
Obstructive Sleep Apnea1 trial
Single Dose1 trial
Cardiovascular1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zopiclone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- GABA-a Receptor; Agonist GABA Site Positive Allosteric Modulator[2]
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- TTaisho Pharmaceutical Co., Ltd.